TeresaLynnHelstenMD(She/Her)

Oncology • La Jolla, CA

Breast Cancer

UC San Diego Health Comprehensive Breast Center Moores Cancer Center

Join to view full profile

Dr. Helsten is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Helsten's full profile

Already have an account?

Office
3855 Health Sciences Dr
#0987
La Jolla, CA 92093
Phone+1 858-249-3249

Fax+1 858-249-3250

Education & Training

University of California (San Diego) Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
Los Angeles County-Harbor-UCLA Medical CenterResidency, Internal Medicine, 1998 - 2002
University of California, Davis, School of MedicineClass of 1998

Certifications & Licensure

CA State Medical License 2000 - 2026

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin Start of enrollment: 2011 Aug 01
Terminated
Phase 1
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2
Study of LEE011, BYL719 and Letrozole in Advanced ER+ Breast Cancer Start of enrollment: 2013 Oct 22
Active, not recruiting
Phase 1, Phase 2
A Neoadjuvant Study of Abemaciclib (LY2835219) in Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Breast Cancer Start of enrollment: 2015 Aug 01
Completed
Phase 2
Lucitanib (E3810) in Patients With Advanced Cancer and FGFR, VEGFR, or PDGFR Pathway Aberrations Start of enrollment: 2017 Apr 01
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

152 citations
Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial
Lajos Pusztai, Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du
Cancer Cell. 2021-07-12
424 citations
Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adapt...
Rita Nanda, Minetta C. Liu, Christina Yau, Rebecca Shatsky, Lajos Pusztai
JAMA Oncology. 2020-05-01
118 citations
Association of Event-Free and Distant Recurrence-Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Can...
Douglas Yee, Angela DeMichele, Christina Yau, Claudine Isaacs, W. Fraser Symmans
JAMA Oncology. 2020-09-01